Table 3.
Independent predictors of 1-year mortality in LFLG AS treated with new-generation THV.
| Clinical variables | HR | P- value | CI 95% | |
|---|---|---|---|---|
| Age, years | 1.00 | 0.873 | 0.97 | 1.04 |
| Female sex | 0.68 | 0.167 | 0.40 | 1.17 |
| Porcelain aorta | 1.84 | 0.161 | 0.78 | 4.34 |
| Hostile chest | 2.75 | 0.126 | 0.75 | 10.01 |
| COPD | 1.78 | 0.036 | 1.04 | 3.05 |
| Previous PCI | 0.53 | 0.052 | 0.28 | 1.01 |
| Concomitant PCI | 0.50 | 0.178 | 0.19 | 1.37 |
| e-GFR | 0.99 | 0.122 | 0.98 | 1.00 |
| EuroSCORE II | 1.02 | 0.021 | 1.00 | 1.04 |
| Mean aortic transvalvular gradient | 0.98 | 0.189 | 0.95 | 1.01 |
COPD, chronic obstructive pulmonary disease; e-GFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention; THV, transcatheter heart valve.